The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

QCR-51     4-[4-[[2-(4-chlorophenyl) phenyl]methyl]pip...

Synonyms: PubChem20162, ABT-737, S1002_Selleck, ABT737, CHEMBL376408, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of ABT-737

 

Associations of ABT-737 with other chemical compounds

 

Gene context of ABT-737

  • DR5 up-regulation induced by ABT-737 treatment occurred through a transcriptional mechanism, and mutagenesis studies demonstrated that the NF-kappaB site found in the DR5 promoter was essential for the ability of ABT-737 to increase the levels of this mRNA [7].

References

  1. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Witham, J., Valenti, M.R., De-Haven-Brandon, A.K., Vidot, S., Eccles, S.A., Kaye, S.B., Richardson, A. Clin. Cancer Res. (2007) [Pubmed]
  2. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Okumura, K., Huang, S., Sinicrope, F.A. Clin. Cancer Res. (2008) [Pubmed]
  3. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Kline, M.P., Rajkumar, S.V., Timm, M.M., Kimlinger, T.K., Haug, J.L., Lust, J.A., Greipp, P.R., Kumar, S. Leukemia (2007) [Pubmed]
  4. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Chauhan, D., Velankar, M., Brahmandam, M., Hideshima, T., Podar, K., Richardson, P., Schlossman, R., Ghobrial, I., Raje, N., Munshi, N., Anderson, K.C. Oncogene (2007) [Pubmed]
  5. ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents. Touzeau, C., Dousset, C., Bodet, L., Gomez-Bougie, P., Bonnaud, S., Moreau, A., Moreau, P., Pellat-Deceunynk, C., Amiot, M., Le Gouill, S. Clin. Cancer Res. (2011) [Pubmed]
  6. Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. Tromp, J.M., Geest, C.R., Breij, E.C., Elias, J.A., van Laar, J., Luijks, D.M., Kater, A.P., Beaumont, T., van Oers, M.H., Eldering, E. Clin. Cancer Res. (2012) [Pubmed]
  7. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. Song, J.H., Kandasamy, K., Kraft, A.S. J. Biol. Chem. (2008) [Pubmed]
 
WikiGenes - Universities